Skip to main content

Table 2 Active EAE induction with hPLP peptides

From: DQB1*0602 rather than DRB1*1501 confers susceptibility to multiple sclerosis-like disease induced by proteolipid protein (PLP)

HLA Tg mice Immunization Incidence Maximal clinical severity Day of onset
DRB1*1501 hPLP30-51 0/4 -- --
  hPLP30-51* 0/4 -- --
  hPLP41-60 0/4 -- --
  hPLP41-60* 0/4 -- --
  hPLP95-116* 0/4 -- --
  hPLP139-151* 0/3 -- --
  hPLP175-194 0/3 -- --
  hPLP175-194* 0/4 -- --
  hPLP185-206 0/3 -- --
  hPLP185-206* 0/9 -- --
  hPLP195-216 0/3 -- --
  hPLP195-216* 0/4 -- --
  hPLP206-226 0/3 -- --
  hPLP206-226* 0/3 -- --
  hPLP257-276* 0/3 -- --
  hΔPLP* 0/4 -- --
DQB1*0602 hPLP30-51 0/2 -- --
  hPLP30-51* 0/4 -- --
  hPLP84-102 0/2 -- --
  hPLP139-151* 6/15 1,2,1,1,1,1 13,15,16,13,14,14
  hPLP175-194* 5/9 2,3,1,3,1 13,14,15,20, 21
  h175-183S-194* 0/5 -- --
  hPLP206-226 0/3 -- --
  hPLP206-226* 0/4 -- --
  hPLP215-235 0/4 -- --
  hPLP215-235* 0/4 -- --
  hPLP257-276 0/8 -- --
  hPLP257-276* 0/4 -- --
  hΔPLP*, ** 0/8 -- --
  1. Mice were injected with 200 μg of PLP peptide or hΔPLP, and received 300 ng PT immediately and after 48 h (protocol 1)
  2. *, Mice received a boost after a week (protocol 2)
  3. **, The Cys to Ser replacements in the hΔPLP abrogated the encephalitogeinc potential of epitopes, as shown here for PLP175-183Cys/Ser-194 mutated peptide and detailed in Results